Triglyceride-mimetic prodrugs: design principles, structural optimization, and implications for lymphatic transport and oral bioavailability
Related Experiment Video
Updated: Nov 7, 2026

The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport
Published on: March 6, 2015
Muyasaer Aisan1, Shujing Yan1, Shijie Du1
1College of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang, China.
Abstract:
Triglyceride (TG)-mimetic prodrugs represent an innovative drug delivery strategy. Through chemical modification, drugs are conjugated to the TG backbone to enhance lymphatic transport capacity and oral bioavailability. This design effectively circumvents first-pass hepatic metabolism, promotes drug accumulation in the mesenteric lymph, and consequently enhances bioavailability. This review summarizes the design principles and advantages of TG-mimetic prodrugs, as well as their applications to drugs with diverse physicochemical properties, with a particular emphasis on how the structural features of TG-mimetic prodrugs influence their in vivo behavior. By optimizing the structure of TG prodrugs, their stability, lymphatic targeting ability, and bioavailability can be significantly improved, thereby providing a robust theoretical foundation and novel insights for the development of future drug delivery systems.
Related Concept Videos
Bioavailability Enhancement: Drug Permeability Enhancement
Prodrugs
Prodrugs help overcome...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

